Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
31,500
Employees31,500
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
31,500
Employees31,500

AMGN Key Statistics

Market cap
224.22B
Market cap224.22B
Price-Earnings ratio
25.76
Price-Earnings ratio25.76
Dividend yield
2.40%
Dividend yield2.40%
Average volume
3.37M
Average volume3.37M
High today
$415.20
High today$415.20
Low today
$404.19
Low today$404.19
Open price
$407.45
Open price$407.45
Volume
2.21M
Volume2.21M
52 Week high
$447.03
52 Week high$447.03
52 Week low
$269.77
52 Week low$269.77

Stock Snapshot

The current Amgen(AMGN) stock price is $414.80, with a market capitalization of 224.22B. The stock trades at a price-to-earnings (P/E) ratio of 25.76 and offers a dividend yield of 2.40%.

On 2026-09-26, Amgen(AMGN) stock traded between a low of $404.19 and a high of $415.20. Shares are currently priced at $414.80, which is +2.6% above the low and -0.1% below the high.

The Amgen(AMGN)'s current trading volume is 2.21M, compared to an average daily volume of 3.37M.

In the last year, Amgen(AMGN) shares hit a 52-week high of $447.03 and a 52-week low of $269.77.

In the last year, Amgen(AMGN) shares hit a 52-week high of $447.03 and a 52-week low of $269.77.

AMGN News

Simply Wall St 15h
How Phase 3 Sjögren’s Results At Amgen Has Changed Its Investment Story

Amgen reported positive topline Phase 3 OASIZ 301 data for dazodalibep in adults with moderate-to-severe systemic Sjögren’s disease, with statistically signific...

How Phase 3 Sjögren’s Results At Amgen Has Changed Its Investment Story
Zacks 20h
Amgen Rises Higher Than Market: Key Facts

In the latest close session, Amgen (AMGN Quick QuoteAMGN - Free Report) was up +2.11% at $414.61. The stock's change was more than the S&P 500's daily gai...

Amgen Rises Higher Than Market: Key Facts
24/7 Wall St. 2d
How a Roth IRA Can Keep Thousands More of Your DJIA Dividend Income Compounding

Investing How a Roth IRA Can Keep Thousands More of Your DJIA Dividend Income Compounding Holding blue-chip Dow dividend payers in a taxable account quietly han...

How a Roth IRA Can Keep Thousands More of Your DJIA Dividend Income Compounding

Analyst ratings

51%

of 37 ratings
Buy
32.4%
Hold
51.4%
Sell
16.2%

More AMGN News

Simply Wall St 2d
Amgen Stock Could Be 40% Undervalued On Phase 3 Sjögren’s Data

has delivered a strong run over the past several years and now trades near US$406, which naturally raises the question of whether that price is fully supported...

Amgen Stock Could Be 40% Undervalued On Phase 3 Sjögren’s Data
Nasdaq 3d
AMGN Crosses Above Average Analyst Target

In recent trading, shares of Amgen Inc (Symbol: AMGN) have crossed above the average analyst 12-month target price of $239.88, changing hands for $241.01/share....

AMGN Crosses Above Average Analyst Target
TipRanks 3d
Amgen: Strengthening Pipeline and Long-Term Growth Upside Support Buy Rating and Unchanged $450 Price Target

Salveen Richter, an analyst from Goldman Sachs, maintained the Buy rating on Amgen. The associated price target remains the same with $450.00. Salveen Richter...

TipRanks 3d
Amgen Underperform Maintained as Dazodalibep Data Uncertainty Limits Upside; $317 Price Target Unchanged

Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Sell rating on Amgen. The associated price target remains the same with $317.00. Tazeen...

Simply Wall St 3d
Amgen Following Its Sjögren's Trial Win Through A Valuation Lens

Amgen (AMGN) has become a focal point for autoimmune investors after releasing Phase 3 data showing its experimental drug dazodalibep met the primary endpoint i...

Amgen Following Its Sjögren's Trial Win Through A Valuation Lens
TipRanks 4d
Competitive profile of Amgen’s dazodalibep still ‘open question,’ says Citi

Citi says Amgen’s (AMGN) dazodalibep delivered “positive” Phase 3 results in systemic Sjogren’s, which reduces clinical risk for “a potentially underappreciated...

Investor's Business Daily 4d
Amgen Boasts Success In Sjogren's; Shares Charge Ahead

Technology Amgen Boasts Success In Sjogren's; Shares Charge Ahead Licensing Amgen (AMGN) stock bounded above its 50-day line Tuesday after publishing promising...

Amgen Boasts Success In Sjogren's; Shares Charge Ahead

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.